AbbVie (ABBV)
(Delayed Data from NYSE)
$201.68 USD
+1.21 (0.60%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.68 USD
+1.21 (0.60%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
by Zacks Equity Research
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.
Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.
The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.
Top Stock Reports for Facebook, Netflix & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).
3 Top Lessons Learned from Buffett's 2020 Portfolio Moves
by Tracey Ryniec
During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?
Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie
by Zacks Equity Research
Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie
AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
by Zacks Equity Research
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
3 Top Lessons Learned from Buffett's 2020 Portfolio Moves
by Tracey Ryniec
During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
Bausch (BHC) Begins Second Phase III Study on NOV03 for DED
by Zacks Equity Research
Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.
The Zacks Analyst Blog Highlights: AbbVie, Square, Honda Motor, Canadian Pacific Railway and Wayfair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Square, Honda Motor, Canadian Pacific Railway and Wayfair
Is AbbVie (ABBV) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
Top Analyst Reports for AbbVie, Square & Honda Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Square, Inc. (SQ) and Honda Motor Co., Ltd. (HMC).
Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track
by Zacks Equity Research
ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.
Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus
by Zacks Equity Research
Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.
Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.
AbbVie (ABBV) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
AbbVie (ABBV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
Company News for Nov 2, 2020
by Zacks Equity Research
Companies In The News Are: ABBV, HON, CVX, RCL
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.
AbbVie (ABBV) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 2.91% and 1.83%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?